2025-05-08-Jefferies-阿泰尔制药（ATYR）_2025年第一季度肺结节病3期试验顶线数据有望在2025年第三季度公布_9页_1mb

Company Update and Key Clinical Trials:
aTyr Pharma is a clinical-stage biotechnology firm focusing on treatments for fibrosis and inflammation. The lead drug, efzofitimod (NRP2), is advancing in clinical development. The Phase 3 pivotal study for pulmonary sarcoidosis is on track for top-line results in 3Q2025, with baseline data to be presented at ATS2025. This study, a randomized controlled trial with 52 weeks and 268 participants, evaluates steroid reduction and symptom improvement. An interim Phase 2 analysis for systemic sclerosis-ILD (SSc-ILD) is expected in 2Q2025, focusing on skin assessments with limited read-out impact.

Financial Status and Runway:
The company has $78.8 million in cash and expects sufficient funding for operations through 1 year post-Phase 3 readout. R&D expenses reached $11.8 million, with a market capitalization of $281.2 million. A price target of $9.00 (+185% from current $3.16) is set, alongside a base case value driven by potential commercial success.

Investment Thesis and Valuation:
efzofitimod targets a large, untapped market for pulmonary sarcoidosis with no approved drugs, potentially generating up to $550 million in US peak sales. Additional opportunities in SSc-ILD and other ILDs are expected. Valuation is DCF-based, with risks centered on clinical, regulatory, and supply chain factors. Analysts recommend a "Buy" rating, citing upside from market opportunities.

Catalysts and Risks:
Key catalysts include the 3Q2025 Phase 3 top-line results and the 2Q2025 Phase 2 interim readout. Risks involve supply chain reliability, product quality, and employee engagements from prior agreements. Short-term financial targets are conservative, with upside scenarios projecting up to $15.00 by 2026.

Market Context and Product Pipeline:
Efzofitimod leverages a novel immunomodulator platform, addressing ILD and fibrosis with a growing pipeline of candidates. While pulmonary sarcoidosis is the current focus, the broader market opportunity includes other inflammatory conditions.